Investors Buy Large Volume of COMPASS Pathways Call Options (NASDAQ:CMPS)

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) saw unusually large options trading activity on Friday. Stock investors bought 7,423 call options on the company. This is an increase of approximately 152% compared to the average daily volume of 2,940 call options.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. BTIG Research lifted their price target on COMPASS Pathways from $7.00 to $14.00 and gave the company a “buy” rating in a report on Monday, October 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of COMPASS Pathways in a research note on Wednesday. Royal Bank Of Canada boosted their target price on shares of COMPASS Pathways from $16.00 to $21.00 and gave the stock an “outperform” rating in a report on Friday. Finally, Morgan Stanley raised their price target on shares of COMPASS Pathways from $10.00 to $11.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $16.25.

COMPASS Pathways Price Performance

Shares of CMPS stock opened at $7.17 on Friday. The firm has a market capitalization of $688.46 million, a price-to-earnings ratio of -2.64 and a beta of 1.92. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.23 and a current ratio of 1.23. The stock’s 50-day simple moving average is $6.42 and its 200-day simple moving average is $5.58. COMPASS Pathways has a fifty-two week low of $2.25 and a fifty-two week high of $8.20.

COMPASS Pathways (NASDAQ:CMPS) last released its earnings results on Tuesday, November 4th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02. As a group, equities analysts forecast that COMPASS Pathways will post -2.33 earnings per share for the current fiscal year.

Hedge Funds Weigh In On COMPASS Pathways

Hedge funds have recently made changes to their positions in the company. Royal Bank of Canada raised its stake in COMPASS Pathways by 49.8% in the 1st quarter. Royal Bank of Canada now owns 89,446 shares of the company’s stock worth $256,000 after acquiring an additional 29,733 shares during the last quarter. Acadian Asset Management LLC raised its stake in shares of COMPASS Pathways by 42.0% in the first quarter. Acadian Asset Management LLC now owns 240,591 shares of the company’s stock worth $686,000 after purchasing an additional 71,112 shares during the last quarter. Stableford Capital II LLC purchased a new position in shares of COMPASS Pathways in the second quarter worth about $459,000. Conservest Capital Advisors Inc. lifted its holdings in shares of COMPASS Pathways by 32.5% during the second quarter. Conservest Capital Advisors Inc. now owns 20,363 shares of the company’s stock worth $57,000 after purchasing an additional 5,000 shares during the period. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its position in COMPASS Pathways by 67.0% in the second quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 23,842 shares of the company’s stock valued at $67,000 after buying an additional 9,569 shares during the last quarter. 46.19% of the stock is owned by institutional investors and hedge funds.

About COMPASS Pathways

COMPASS Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, COMPASS Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.